News Focus
News Focus
icon url

surf1944

05/02/13 8:30 AM

#145 RE: surf1944 #144

7:09AM Incyte beats by $0.06, beats on revs (INCY) 21.52 : Reports Q1 (Mar) loss of $0.12 per share, $0.06 better than the Capital IQ Consensus Estimate of ($0.18); revenues rose 96.4% year/year to $71.1 mln vs the $68.16 mln consensus. The increase in total revenues from the first quarter of 2012 to the first quarter of 2013 was primarily related to increased Jakafi product revenue and $5.9 mln of Jakavi product royalties from Novartis.

Cash Position
As of March 31, 2013, cash, cash equivalents and marketable securities totaled $270.2 mln compared to $228.4 mln as of December 31, 2012.